Federal Register Proposed rule and direct final rule: FDA is proposing to amend the biologics regulations by providing options to the existing requirement for live vaccine processing. Advances in technology will allow live vaccines to be processed in multi-product manufacturing areas. The agency says the existing requirement on facilities and equipment is too prescriptive and is no longer necessary. To view this proposed rule, click here.
